Table 5. Comparison of 87 NSCLC patient characteristics between the grade ≥2 RILI group and the grade <2 RILI group.
| Factors | Grade ≥2 RILI (N=16) | Grade <2 RILI (N=71) | P value |
|---|---|---|---|
| Gender | 0.045 | ||
| Male | 16 | 57 | |
| Female | 0 | 14 | |
| Age (years) | 0.372 | ||
| >65 | 7 | 37 | |
| ≤65 | 9 | 34 | |
| Complication | 0.129 | ||
| Yes | 5 | 36 | |
| No | 11 | 35 | |
| Smoking history (packs-year) | 0.137 | ||
| >30 | 12 | 40 | |
| ≤30 | 4 | 31 | |
| Tumor location | 1.000 | ||
| Peripheral | 11 | 50 | |
| Central | 5 | 21 | |
| Pathology | 0.139 | ||
| Squamous | 6 | 40 | |
| Non-squamous | 10 | 31 | |
| T stage | 0.531 | ||
| T1–2 | 12 | 55 | |
| T3–4 | 4 | 16 | |
| N stage | 0.548 | ||
| N0–1 | 8 | 34 | |
| N2-3 | 8 | 37 | |
| Radiotherapy technology | 0.600 | ||
| SBRT | 5 | 22 | |
| IMRT | 11 | 49 | |
| Chemotherapy | 0.372 | ||
| Yes | 7 | 37 | |
| No | 9 | 34 | |
| Concurrent CRT | 0.533 | ||
| Yes | 4 | 20 | |
| No | 12 | 51 | |
| Target therapy | 0.523 | ||
| Yes | 2 | 7 | |
| No | 14 | 64 | |
| rs11615 | 0.581 | ||
| G allele | 10 | 45 | |
| A allele | 6 | 26 | |
| rs3212961 | 0.376 | ||
| G allele | 3 | 19 | |
| T allele | 13 | 52 | |
| rs3212986 | 0.372 | ||
| C allele | 9 | 34 | |
| A allele | 7 | 37 | |
| rs13181 | 0.616 | ||
| T allele | 14 | 61 | |
| G allele | 2 | 10 | |
| rs238406 | 0.533 | ||
| G allele | 4 | 20 | |
| T allele | 12 | 51 | |
| rs1799793 | 0.523 | ||
| C allele | 14 | 64 | |
| T allele | 2 | 7 |
NSCLC, non-small cell lung cancer; RILI, radiation-induced lung injury; CRT, chemoradiotherapy.